CARB-X announced two new investments on Tuesday. The first, worth up to $8.77 million, will go to Germany’s Helmholtz Centre for Infection Research (HZI) and the Dortmund-based Lead Discovery Center to develop a drug to prevent S. aureus-induced lung tissue damage in pneumonia patients. The second award—up to $6.31 million to a team of HZI-affiliated researchers—will fund the development of a new treatment for P. aeruginosa infections in cystic fibrosis patients.

In other news, the…